Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    4
    ...
ATC Name B/G Ingredients Dosage Form Price
J05AF05 VICONDINE G Lamivudine - 150mg 150mg Tablet, film coated 3,573,725 L.L
A10BD08 VLUDIN MET G Metformin HCl - 850mg, Vildagliptin - 50mg Tablet, film coated 735,914 L.L
J05AF07 VIREAD B Tenofovir disoproxil - 245mg 245mg Tablet, film coated 15,716,313 L.L
J01AA08 VULGA XR G Minocycline - 105mg 105mg Tablet, film coated 3,682,128 L.L
J01AA08 VULGA XR G Minocycline - 80mg 80mg Tablet, film coated 2,832,820 L.L
J01AA08 VULGA XR G Minocycline - 55mg 55mg Tablet, film coated 1,983,512 L.L
A10BD13 VIPDOMET B Metformin HCl - 500mg, Alogliptin benzoate - 12.5mg Tablet, film coated 3,112,339 L.L
A10BD13 VIPDOMET B Metformin HCl - 1,000mg, Alogliptin benzoate - 12.5mg Tablet, film coated 3,304,509 L.L
J05AF13 VEMLIDY B Tenofovir alafenamide fumarate - 25mg 25mg Tablet, film coated 26,997,299 L.L
B01AF01 VAROXA G Rivaroxaban - 15mg 15mg Tablet, film coated 1,343,843 L.L
N03AG01 VALPROATE DE SODIUM ARROW LP G Sodium valproate - 500mg 500mg Tablet, coated, scored, prolonged release 253,986 L.L
N05AH03 VAINCOR G Olanzapine - 5mg 5mg Tablet, coated, scored 806,306 L.L
N05AH03 VAINCOR G Olanzapine - 10mg 10mg Tablet, coated, scored 1,209,458 L.L
J02AC03 VORICONAZOLE STRAGEN G Voriconazole - 50mg 50mg Tablet, coated 15,808,184 L.L
J02AC03 VORICONAZOLE STRAGEN G Voriconazole - 200mg 200mg Tablet, coated 41,794,841 L.L
J05AB14 VALGANCICLOVIR ARROW G Valganciclovir (HCl) - 450mg 450mg Tablet, coated 46,063,879 L.L
L01XX52 VENCLEXTA B Venetoclax - 100mg 100mg Tablet 707,858,935 L.L
L01XX52 VENCLEXTA B Venetoclax - 10mg week 1, Venetoclax - 50mg week 2, Venetoclax - 100mg week 3&4 Tablet 190,943,809 L.L
P02CA01 VERMOX B Mebendazole - 500mg 500mg Tablet 106,164 L.L
P02CA01 VERMOX B Mebendazole - 500mg 500mg Tablet 106,164 L.L
P02CA01 VERMOX B Mebendazole - 100mg 100mg Tablet 190,826 L.L
P02CA01 VERMOX B Mebendazole - 100mg 100mg Tablet 190,826 L.L
A10BH02 VILDAVITAE G Vildagliptin - 50mg 50mg Tablet 665,202 L.L
A10BH02 VILDIAB G Vildagliptin - 50mg 50mg Tablet 806,306 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
M01AB05 VOLDIC-K G Diclofenac potassium - 50mg 50mg Tablet 239,204 L.L
G04BE03 VIGORAM G Sildenafil citrate - 50mg 50mg Tablet 330,585 L.L
R06AE55 VOMINORE-JPM G Meclozine HCl - 25mg, Pyridoxine HCl - 50mg Tablet 259,362 L.L
L01EF03 VERZENIO B Abemaciclib - 150mg 150mg Tablet 76,122,299 L.L
    4
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025